Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.48 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21805747 | 0.90 | P2RY10 (0.53) | FOLH1NAALAD2P2RY10GPR34DGKA | |
| SCHEMBL8083537 | 0.82 | GRM3 (0.46) | FOLH1NAALAD2P2RY10GPR34 | |
| SCHEMBL15068278 | 0.80 | FOLH1 (0.62) | FOLH1NAALAD2 | |
| SCHEMBL9714134 | 0.80 | FOLH1 (0.62) | FOLH1NAALAD2 | |
| SCHEMBL9714012 | 0.80 | FOLH1 (0.62) | FOLH1NAALAD2 | |
| SCHEMBL18675750 | 0.80 | DGKA (0.57) | P2RY10GPR34NAAADGKAHTR2C | |
| SCHEMBL15396413 | 0.80 | FOLH1 (0.50) | FOLH1NAALAD2 | |
| SCHEMBL11227144 | 0.78 | NAAA (0.50) | P2RY10GPR34NAAADGKAHTR2C | |
| SCHEMBL11223465 | 0.78 | NAAA (0.50) | P2RY10GPR34NAAADGKAHTR2C | |
| SCHEMBL8359802 | 0.78 | DGKA (0.62) | P2RY10GPR34NAAADGKAHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166087-B | Screening agent and use thereof | 恩多塞特公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3853213-A1 | SHIELDING AGENTS AND THEIR USE | Endocyte, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113166087-A | Shielding agent and application thereof | 恩多塞特公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020061293-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | PSMA6, PSMA2, PSMA1 | FOLH1 10/4885NAALAD2 1086/4885P2RY10 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.